

SEP 21 2006

Attorney Docket 036870-5073-02
U.S. Application 10/772,437
Page 2

Amendments to the Claims:

This listing of claims will replace all prior versions and listing of claims in the application.

Claims 1 to 36 (cancelled)

37. (currently amended) A method of treating a condition associated with atopic allergy or asthma in disease associated with ICACC protein activity in the airways of a patient comprising administering to the patient in need of treatment an effective amount of an antibody which binds to ICACC-1 (SEQ ID NO: 6) agent to ~~modulate the activity of the ICACC protein.~~

38. (cancelled).

39. (currently amended) The method of claim ~~[[38]]~~ 37, wherein the agent down-regulates the activity of the ~~ICACC~~ ICACC-1 protein.

40. (cancelled)

41. (currently amended) The method according to claim any of claims 37 to 39, wherein the agent causes a decrease in bronchial hyperresponsiveness.

42. (currently amended) The method according to claim any of claims 37 to 39, wherein the agent causes a decrease in inflammatory cells in the airways of the patient.

43. (previously presented) The method according to claim 42, wherein the cells are selected from the group consisting of mast cells, eosinophils, lymphocytes and epithelial cells.

44. (currently amended) The method according to claim any of claims 37 to 40, wherein the agent causes an improvement in pulmonary function.

45 to 51. (cancelled)

52. (currently amended) The method according to claim ~~[[51]]~~ 37, wherein the antibody is monoclonal.

Attorney Docket 036870-5073-02
U.S. Application 10/772,437
Page 3

53 to 54. (cancelled)

55. (currently amended) The method according to claim ~~any of claims 37 to 40 or 45~~, wherein the antibody agent is administered by inhalation.

56. (currently amended) The method according to claim 55, wherein the antibody agent is administered by an inhalation device.

57. (currently amended) The method according to claim 56, wherein the antibody agent is administered by a metered dose inhaler.

58. (currently amended) The method according to claim 56, wherein the antibody agent is administered by a dry powder inhaler.

59. (cancelled)

60. (currently amended) The method according to claim ~~[[59]]~~ 37, wherein the antibody agent is administered intravenously.

61. (currently amended) The method according to claim ~~any of claims 37 to 40 or 45~~, wherein the patient is human.